Research from Redeye, Redeye AB

Redeye

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye leaves a short comment following OncoZenge’s announcement of having received the third tranche from its investment agreement with Yangtian.</li><li>We are encouraged to see that the company has resolved the recent short-term financing uncertainty, restoring stability and maintaining momentum ahead of the upcoming phase III CTA milestone.</li></ul>

Redeye leaves a short comment following OncoZenge’s announcement of having received the third tranche from its investment agreement with Yangtian.We are encouraged to see that the company has resolved the recent short-term financing uncertainty, restoring stability and maintaining momentum ahead of the upcoming phase III CTA milestone.

OncoZenge: Previous financing delays now resolved

<ul><li>Redeye leaves a comment following OncoZenge’s announcement of the completed readout from its UCLA-led patient engagement study for BupiZenge.</li><li>We are encouraged to see that the study not only confirms the significant unmet need in oral mucositis pain, but that its insights have already been integrated into the phase III protocol and CTA, representing a concrete de-risking step ahead of the pivotal trial.</li></ul>

Redeye leaves a comment following OncoZenge’s announcement of the completed readout from its UCLA-led patient engagement study for BupiZenge.We are encouraged to see that the study not only confirms the significant unmet need in oral mucositis pain, but that its insights have already been integrated into the phase III protocol and CTA, representing a concrete de-risking step ahead of the pivotal trial.

OncoZenge: Insights from UCLA Patient Engagement Study

<ul><li>Redeye leaves a comment following OncoZenge’s announcement of a SEK5m bridge financing via a convertible note with Linc and the formal payment commitment from Yangtian for the delayed third tranche.</li><li>We are encouraged to see that the company has acted swiftly and decisively to stabilize its short-term financial position, effectively removing the acute liquidity risk and safeguarding continued execution of its strategic and regulatory plans.</li></ul>

Redeye leaves a comment following OncoZenge’s announcement of a SEK5m bridge financing via a convertible note with Linc and the formal payment commitment from Yangtian for the delayed third tranche.We are encouraged to see that the company has acted swiftly and decisively to stabilize its short-term financial position, effectively removing the acute liquidity risk and safeguarding continued execution of its strategic and regulatory plans.

OncoZenge: SEK5m convertible loan agreement with Linc

<ul><li>Redeye leaves a comment following OncoZenge’s announcement regarding the delayed payment of tranche 3 from the investment agreement with Yangtian.</li><li>We believe that this introduces short-term financing uncertainty, but does not, in our view, alter the underlying strategic case.</li></ul>

Redeye leaves a comment following OncoZenge’s announcement regarding the delayed payment of tranche 3 from the investment agreement with Yangtian.We believe that this introduces short-term financing uncertainty, but does not, in our view, alter the underlying strategic case.

OncoZenge: Delayed payment from investment agreement

<ul><li>Redeye leaves a comment following OncoZenge’s announcement of having submitted the Clinical Trial Application for its pivotal phase III trial of BupiZenge.</li><li>We view this as an important milestone that confirms the company’s transition from preparation to execution and materially advances BupiZenge toward a potential European market approval.</li></ul>

Redeye leaves a comment following OncoZenge’s announcement of having submitted the Clinical Trial Application for its pivotal phase III trial of BupiZenge.We view this as an important milestone that confirms the company’s transition from preparation to execution and materially advances BupiZenge toward a potential European market approval.

OncoZenge: CTA for phase III study submitted

Sweden

OncoZenge AB (publ), a pharmaceutical company, engages in the a development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Oncozenge (ONCOZ SF)

OncoZenge: Previous financing delays now resolved

Redeye leaves a short comment following OncoZenge’s announcement of having received the third tranche from its investment agreement with...

Redeye

OncoZenge: Insights from UCLA Patient Engagement Study

Redeye leaves a comment following OncoZenge’s announcement of the completed readout from its UCLA-led patient engagement study for BupiZenge. We...

Redeye

OncoZenge: SEK5m convertible loan agreement with Linc

Redeye leaves a comment following OncoZenge’s announcement of a SEK5m bridge financing via a convertible note with Linc and the formal payment...

Redeye

OncoZenge: Delayed payment from investment agreement

Redeye leaves a comment following OncoZenge’s announcement regarding the delayed payment of tranche 3 from the investment agreement with...

Redeye

OncoZenge: CTA for phase III study submitted

Redeye leaves a comment following OncoZenge’s announcement of having submitted the Clinical Trial Application for its pivotal phase III trial of...

Redeye

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)